AC Immune’s (ACIU) “Buy” Rating Reaffirmed at BTIG Research

BTIG Research reiterated their buy rating on shares of AC Immune (NASDAQ:ACIU) in a research note released on Wednesday morning,Benzinga reports. The brokerage currently has a $8.00 target price on the stock.

A number of other research analysts have also recently weighed in on ACIU. Weiss Ratings reiterated a “sell (e+)” rating on shares of AC Immune in a research report on Wednesday, August 5th. HC Wainwright reaffirmed a “buy” rating on shares of AC Immune in a research report on Monday, August 24th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $7.50.

AC Immune Price Performance

NASDAQ ACIU opened at $2.83 on Wednesday. The company’s 50 day moving average is $2.55 and its two-hundred day moving average is $2.68. The company has a current ratio of 0.93, a quick ratio of 1.02 and a debt-to-equity ratio of 0.11. The stock has a market cap of $288.01 million, a price-to-earnings ratio of -5.24 and a beta of 1.60. AC Immune has a 12 month low of $2.10 and a 12 month high of $4.00.

AC Immune (NASDAQ:ACIU) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.03 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.13. The firm had revenue of $18.67 million during the quarter, compared to analyst estimates of $9.59 million. AC Immune had a negative return on equity of 100.17% and a negative net margin of 245.32%. As a group, research analysts anticipate that AC Immune will post -0.6 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. AXQ Capital LP purchased a new stake in AC Immune during the second quarter valued at approximately $25,000. Arrowstreet Capital Limited Partnership grew its holdings in AC Immune by 8.0% in the first quarter. Arrowstreet Capital Limited Partnership now owns 405,658 shares of the company’s stock worth $1,116,000 after purchasing an additional 30,035 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its position in shares of AC Immune by 82.8% during the first quarter. Dimensional Fund Advisors LP now owns 390,165 shares of the company’s stock worth $1,071,000 after purchasing an additional 176,701 shares in the last quarter. 51.36% of the stock is owned by institutional investors.

About AC Immune

AC Immune SA (NASDAQ: ACIU) is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland. Founded in 2003, the company develops precision medicines and diagnostic products designed to prevent, diagnose and treat neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease and other conditions associated with misfolded proteins.

AC Immune’s research is based on its SupraAntigen and Morphomer technology platforms, which are intended to identify disease-related proteins and generate therapies or diagnostic tools that target them.